Stuart Poulton
Equibles does not estimate personal net worth.
About Stuart Poulton
Karyopharm Therapeutics Inc. reported in an 8-K filed July 28, 2022 that Stuart Poulton was appointed Executive Vice President, Chief Development Officer, effective July 27, 2022. The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $1,399,580 for Stuart Poulton in fiscal 2025, including a base salary of $500,135. Disclosed compensation is on record for 4 fiscal years. Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Karyopharm Therapeutics Inc. includes Richard Paulson (CEO and Board Member), Senior Clinical (CEO), Michael Mano (General Counsel) and 7 others.
“Stuart Poulton, who has served as the Company's Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.”
Affiliation history
-
Karyopharm Therapeutics Inc. (KPTIQ)
Proxy statement
CurrentStart not stated–present
Last confirmed April 13, 2026
Company network
Leadership on record at Karyopharm Therapeutics Inc.
- Richard Paulson CEO, Board Member
- Senior Clinical CEO
- Michael Mano General Counsel
- Kristin Abate Chief Accounting Officer
- Barry E. Greene Board Member
- Chen Schor Board Member
- Christy J Oliger Board Member
- Christy J. Oliger Board Member
- Deepika R. Pakianathan Board Member
- Garen G. Bohlin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Karyopharm Therapeutics Inc. (KPTIQ) | Executive Vice President, Chief Development Officer | $500,135 | $1,399,580 |
| 2024 | Karyopharm Therapeutics Inc. (KPTIQ) | Executive Vice President, Chief Development Officer | — | — |
| 2023 | Karyopharm Therapeutics Inc. (KPTIQ) | Chief Development Officer | $477,000 | $1,109,115 |
| 2022 | Karyopharm Therapeutics Inc. (KPTIQ) | Chief Development Officer | $373,910 | $1,795,247 |